Tianjin, China, November 7, 2020, CanSino Biologics Inc. (“CanSinoBIO”) (SHSE: 688185, HKEX:06185) announced that it has launched the Phase III clinical trial for the Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) ("Ad5-nCoV") in Mexico and has successfully vaccinated the first group of subjects. The study has been approved by the Mexican authority in October. The trial aims to recruit a total number of 15000 subjects to further demonstrate the efficacy of the candidate.
CanSinoBIO has been working closely with the local company EPIC RESERCH S de RL de CV (“EPIC”) to move the clinical study forward. In the past October, CanSinoBIO has also signed an advance purchase agreement with the Mexico government to supply 35 million doses of COVID-19 vaccine to the Mexicans in need.
On November 6th, the first group of subjects in Mexico got vaccinated.
Dr. Xuefeng Yu, Chairman and CEO of CanSinoBIO stated, “Launching the clinical study of Ad5-nCoV in Mexico represents another milestone of CanSinoBIO. We are delighted to collaborate with EPIC and the authorities that make this initial clinical study conducted in Mexico possible. Hopefully, we could see the outcome of the study very soon and contributes to the pandemic fight in Mexico.”
Ad5-nCoV has currently been conducting phase III clinical development in both Russia and Pakistan. At the same time, CanSinoBIO has also been in ongoing discussion with other potential collaborators in Latin America with the goal of accelerating the global multi-center clinical development process.
Ad5-nCoV, co-developed by Beijing Institute of Biotechnology (BIB), Academy of Military Medical Sciences, became the first of its kind that has entered the clinical development in March 2020. It is also the first candidate that has respectively published the positive results of the phase I and II clinical studies on the Lancet in May and July. The data has demonstrated that a single-dose injection of the candidate can induce a balanced humoral and cellular immune response. In August, it became the first COVID-19 vaccine candidate in China to be patented.
Incorporated in 2009, CanSinoBIO (SHSE: 688185, HKEX:06185) commits to research, production and commercialization of innovative vaccines for China and global public health. It possesses four integrated platform technologies including adenovirus-based vectors, conjugation, protein design and recombination and formulation. As of today, it has established a robust pipeline of 16 vaccines preventing 13 diseases, including a globally innovative Ebola virus vaccine approved in 2017 as well as the investigational Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector).